HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and foreign trade business. It has established a "1+2+3+4=1" service system and can supply L-Leucine sourced directly from multiple well-known original manufacturers. With over ten years of market experience and technological transformation cooperation with manufacturers, HiSiaddi possesses rich experience in addressing product compliance issues. Below is a case study of HiSiaddi handling L-Leucine compliance problems.
Please contact HiSiaddi customer service if you wish to consult more L-Leucine product compliance issues.
The purchasing party in this cooperation is SANOHEALTH Geneva, a health group headquartered in Geneva, Switzerland. With 31 years of experience focusing on three major tracks: high-end postoperative medical nutrition preparations, high-end sports dietary supplements and kidney disease-specific low-protein nutritional stock solutions across Switzerland, Luxembourg and France, its products are supplied to medical insurance designated pharmacies in Switzerland, clinical nutrition departments of Geneva University Affiliated Hospitals and exclusive nutrition supply chains of the Tour de France cycling team. All finished products comply with the EP European Pharmacopoeia, EU LFGB food regulations, REACH chemical control standards, EFSA food safety specifications and Switzerland’s FOODS import access act. Raw materials are exclusively used for medical preparations and high-end dietary finished products, ranking as a benchmark mid-to-high-end client in the amino acid raw material sector, distinct from low-volume low-price intermediate distributors and feed raw material purchasers.
The group has long purchased pharmacopoeia-grade L-Leucine manufactured by Kyowa Hakko (Japan) and Evonik (Germany), with an annual stable total procurement volume of 28 tons divided into three raw material grades: pharmaceutical capsule grade, refined oral liquid grade and medical nutrition powder grade. Triggered by raw material price hikes from overseas original manufacturers, raised minimum order quantities and extended ocean delivery cycles up to 90 days, it launched a China-origin L-Leucine localized replacement procurement project in 2025.
The client independently contacted three leading domestic amino acid manufacturers to finalize sampling, confirming raw material physical and chemical indicators and purity met EP Pharmacopoeia requirements before finalizing a trial order of 12 tons. However, immediately before finished goods production and scheduled loading for shipment, five critical compliance fatal flaws emerged one after another: missing EU legal entity for REACH compliance, incomplete LFGB raw material filing, lack of official TSE/BSE-free statements, product labels violating EU CLP regulations, and mismatched domestic commodity inspection documents with Swiss import customs clearance standards.
The three raw material manufacturers only held domestic production qualifications without supporting capacity for EU regulation implementation, only capable of issuing national standard COA and domestic production licenses, unable to complete full EU compliance document dossiers. If full compliance documents could not be supplemented within 25 working days, the full container goods would have to be detained on-site or returned and destroyed, exposing the client to huge cumulative losses of 126,000 Euros including scrapped raw materials, production line shutdowns, finished product supply disruptions and liquidated damages to downstream supermarket chains. At this critical juncture, the client terminated direct communication with raw material manufacturers and fully entrusted foreign trade service provider HiSiaddi with overall coordination of full-process compliance rectification, document supplementation, customs clearance and shipment.
EU REACH regulations explicitly stipulate that chemical substances of non-EU origin exported to the EU with annual export volume exceeding 1 ton must entrust a local EU compliance institution as the OR (Only Representative) to complete ECHA registration filing, SVHC high-concern substance testing and SCIP database notification. All three domestic raw material manufacturers failed to complete REACH registration for L-Leucine without contracted local EU ORs, lacking valid REACH registration numbers, registration dossiers and SVHC test reports. Swiss customs clarified that chemical raw materials without valid REACH filing are prohibited from entry and subject to return upon arrival. Manufacturers lack EU compliance teams and are unable to independently complete registration procedures within a short timeframe.
The client’s finished products circulate in Swiss and German markets. As a food and medical nutrition raw material, L-Leucine must complete special LFGB raw material filing in Germany and EU EFSA edible safety assessment documents, with third-party CMA laboratory compliance test reports issued to control limits of heavy metals, solvent residues and fermentation by-products. Domestic manufacturers only hold domestic food production licenses with products tested against national standards, lacking LFGB filing documents and EFSA safety statements adapted to EU standards. Swiss import commodity inspection authorities do not recognize domestic national standard quality inspection reports.
European medical-grade amino acids mandate official TSE/BSE (transmissible spongiform encephalopathy) statements certifying microbial fermentation production processes, zero animal-origin auxiliary materials and no doping of animal-derived proteins, a rigid threshold for hospital medical nutrition raw material access. Domestic manufacturers previously drafted simple self-made statements for the EU market, which failed to comply with European drug authority formats and were not accepted by Swiss drug regulatory authorities.
EU CLP regulations mandate mandatory labeling of chemical raw materials on outer barrels including CAS number (61-90-5), EC number, hazard classification, precautionary statements, EU importer responsible entity information, raw material grade labeling and storage specifications. Original factory packaging only printed Chinese product names, net weight and manufacturer information, missing up to 7 mandatory EU-standard English label items, leading to customs detention of goods upon arrival due to non-compliant labeling.
Factory delivery COA only conducted testing per Chinese Pharmacopoeia items, missing EU-limited indicators including D-form leucine chiral impurities, trace organic solvent residues, microbial limits and heavy metals (arsenic, lead, cadmium). Reports featured chaotic Chinese-English formatting without third-party SGS signatures, unrecognized by Swiss customs for import declaration.
All three production enterprises focused on raw material fermentation production and quality control, with core business centered on domestic sales and low-end feed raw material exports to Southeast Asia. They lacked professional compliance departments proficient in refined cross-border access regulations of the EU and Switzerland, only capable of minor raw material purity adjustments and unable to resolve compliance challenges including cross-border regulatory filing, dossier compilation and label rectification.
HiSiaddi set up a special team consisting of EU compliance specialists, third-party testing coordinators, customs document specialists and on-site factory rectification specialists, following a five-step plan to resolve the five major pain points item by item: complete filing qualifications first → rectify product labels second → retest and issue compliant COA third → supplement full customs clearance documents fourth → arrange booking and shipment fifth.
1. HiSiaddi partnered with a Dutch EU compliance institution to sign a local EU OR for this batch of L-Leucine. Based on existing raw material data from manufacturers, it completed tonnage filing at ECHA (European Chemicals Agency), conducted full testing of 22 SVHC high-concern substances to confirm no excessive restricted substances, and simultaneously completed SCIP database product notification to obtain valid REACH filing numbers and full registration dossiers searchable in official EU systems.
2. For the client’s long-term annual procurement volume of 28 tons, HiSiaddi assisted manufacturers in completing formal REACH registration for the full L-Leucine product category to avoid repeated filing costs for each subsequent batch.
1. HiSiaddi coordinated SGS laboratories with EU qualifications in China to re-sample testing per LFGB and EP Pharmacopoeia standards, adding full testing items including heavy metals, fermentation residues, trace impurities and microorganisms to issue Chinese-English bilingual dual-certified (CMA+SGS) test reports.
2. Based on test data, entrust German compliance institutions to complete LFGB raw material filing and EFSA edible safety assessment statements, issuing raw material safety instructions recognized by Germany’s BfR Federal Institute for Risk Assessment to meet food raw material access standards in both Switzerland and Germany.
HiSiaddi collaborated with the factory’s QA quality department to sort full production line raw material traceability records (fermentation strains, culture medium raw materials, full production process records), compile official standard TSE/BSE statements in compliance with European Pharmacopoeia formats affixed with Chinese-English factory official seals and notarized documents. The statements explicitly certified full plant-based glucose fermentation with zero animal-origin raw material additions, passing format verification by Swiss drug regulatory authorities.
1. HiSiaddi uniformly designed barrel English labels per CLP regulation requirements, fully marking CAS 61-90-5, EC number, product grade, hazard statements, storage and transportation conditions, EU OR enterprise name and address, production batch number and expiry date.
2. On-site factory specialist supervised full replacement of compliant new labels on all 480 25kg packaging barrels of the 12-ton batch, destroying original non-compliant Chinese packaging stickers to ensure uniform standardized labeling on every barrel.
1. Expand test items aligned with EP Pharmacopoeia + Swiss import standards to supplement missing indicators including chiral isomers, solvent residues and trace unknown impurities from original factory reports.
2. SGS issued Chinese-English bilingual COA with institutional signatures on every page plus original factory quality official seals, supporting supplementary notarized copies of factory GMP production qualifications, certificates of origin and sanitary certificates. The full set of documents fully matched declaration elements required by Swiss customs for import clearance.
All compliance documents were fully closed within 22 working days. HiSiaddi assisted domestic manufacturers in completing export commodity inspection and customs declaration, with the full container shipped from Shanghai Port to Geneva Port, Switzerland. Upon goods arrival, full documents including REACH, LFGB, TSE/BSE statements, CLP labels and compliant COA passed dual verification by Swiss customs and local food and drug authorities without port detention or fines, and raw materials were smoothly warehoused at the client’s production plant. The client’s three formulation production lines operated on schedule, completely avoiding production shutdown losses and liquidated damages for breach of contract.
Before quarterly separate shipments of subsequent orders, HiSiaddi intervened in advance during raw material production to lock compliance standards from the raw material launch stage: confirm continuous validity of REACH and LFGB filing before production, complete SGS compliance testing, pre-produce labels and compile full document sets before factory delivery, enabling immediate shipment upon production completion without compliance bottlenecks for each batch. All five batches of the full 28-ton annual order were delivered smoothly without incidents.
1. The Swiss group completely discontinued import of raw materials from Japan and Germany, switching 100% of the annual 28 tons of L-Leucine to domestic supply sources. Comprehensive procurement costs decreased by 24.1%, and delivery cycles were shortened from 90 days to 38 days.
2. During the R&D phase of the client’s new children’s medical nutrition amino acid product in its Luxembourg subsidiary, HiSiaddi was commissioned to conduct pre-judgment of raw material access compliance in advance, sorting out local food regulations and import filing requirements of Luxembourg, adding supporting annual procurement of 7.2 tons.
3. Leveraging EU compliance resources accumulated through this project, HiSiaddi assisted cooperating raw material manufacturers in completing full EU compliance qualifications for all amino acid product lines, helping manufacturers successfully expand high-end medical nutrition clients in the Netherlands and Austria.
The vast majority of domestic L-Leucine manufacturers focus on fermentation manufacturing, proficient in domestic national standard and production control yet lacking professional teams specializing in food, pharmaceutical and chemical regulations across multiple EU countries. They lack expertise in cross-border compliance details including REACH, LFGB, CLP and TSE/BSE, only capable of guaranteeing qualified raw material physical and chemical indicators rather than resolving cross-border access compliance issues. Mid-to-high-end European medical nutrition clients are bound by stringent local drug regulatory and customs regulations, where missing a single compliance document may trigger full-batch return and destruction of goods.
Breaking the single-mode traditional foreign trade business of only supplying goods, HiSiaddi centers its full-chain compliance service, bridging third-party testing, local EU compliance institutions, customs declaration and on-site factory rectification resources to systematically address compliance shortcomings of domestic raw materials exported to the EU. It not only helps mid-to-high-end European clients steadily implement localized raw material procurement and avoid trade risks, but also assists high-quality domestic manufacturers in completing international compliance qualifications and entering the supply chain of European high-end medical nutrition raw materials, realizing long-term win-win results for both supply and demand sides.
Please contact HiSiaddi customer service if you wish to consult more L-Leucine product compliance issues.
+86-13120989737 
info@hisiaddi.com 
English
